Xenetic Biosciences, Inc. (NASDAQ:XBIO) | WebDisclosure

Basculer en Français

8694	Companies
150423	Keywords
85984	Articles
80668	Press releases

Headlines Articles Press releases Xenetic Biosciences, Inc.

Home
Companies
Xenetic Biosciences, Inc.

BRIEF

published on 11/21/2024 at 14:35, 6 months 9 days ago

Xenetic Biosciences Reports Promising Preclinical Results for DNase I and CAR T Cell Therapy in Melanoma

Preclinical Study Melanoma DNase I CAR T Cells Oncology Therapy
BRIEF

published on 11/21/2024 at 14:35, 6 months 9 days ago

Xenetic Biosciences annonce des résultats précliniques prometteurs pour la thérapie par ADNase I et cellules CAR T dans le mélanome

Étude Préclinique Mélanome ADNase I Cellules CAR-T Thérapie Oncologique
PRESS RELEASE

published on 11/21/2024 at 14:30, 6 months 9 days ago

Xenetic Biosciences, Inc. Presents Positive Preclinical Data Highlighting the Potential of Co-Administration of DNase I with CAR T Cells in a Murine Model of Melanoma Lung Metastasis
Xenetic presents preclinical data on DNase I and CAR T cells' synergistic effects in treating solid tumors. Results show promise in modulating tumor microenvironment and enhancing therapeutic responses

Preclinical Data Solid Tumors Xenetic DNase I CAR T Cells
BRIEF

published on 11/13/2024 at 14:35, 6 months 17 days ago

Xenetic Biosciences publie ses résultats financiers du troisième trimestre 2024

Résultats Financiers Développement Clinique Biosciences Xénétiques Plateforme D'oncologie DNase Partenariats Institutionnels
BRIEF

published on 11/13/2024 at 14:35, 6 months 17 days ago

Xenetic Biosciences Reports Q3 2024 Financial Results

Financial Results Xenetic Biosciences Clinical Development DNase Oncology Platform Institutional Partnerships
PRESS RELEASE

published on 11/13/2024 at 14:30, 6 months 17 days ago

Xenetic Biosciences, Inc. Reports Third Quarter 2024 Financial Results
Xenetic Biosciences reports Q3 2024 financial results, progress in DNase-based platform for oncology, partnership with institutional collaborators, and $6.8 million cash balance

Xenetic Biosciences Oncology Q3 2024 Financial Results Institutional Partnerships DNase-based Platform
BRIEF

published on 11/12/2024 at 15:05, 6 months 18 days ago

Xenetic Biosciences annonce des résultats précliniques positifs pour la thérapie par DNase I et anti-CTLA-4 dans le cancer colorectal

Immunothérapie Biosciences Xénétiques Données Précliniques Thérapie À L'ADNase I Carcinome Colorectal
BRIEF

published on 11/12/2024 at 15:05, 6 months 18 days ago

Xenetic Biosciences Reports Positive Preclinical Results for DNase I and Anti-CTLA-4 Therapy in Colorectal Cancer

Xenetic Biosciences Preclinical Data Immunotherapy DNase I Therapy Colorectal Carcinoma
PRESS RELEASE

published on 11/12/2024 at 15:00, 6 months 18 days ago

Xenetic Biosciences, Inc. Presents Positive Data Demonstrating DNase I Significantly Improves Efficacy of Anti-CTLA-4 Immune Checkpoint Blockade in Preclinical Colorectal Carcinoma Models
Positive preclinical data on systemic DNase I combined with CTLA-4 antibody presented at SITC 2024, targeting NETs to enhance antitumor immunity and generate immunological memory in MSS/MMRp CRC tumors

DNase I SITC 2024 CTLA-4 Antibody Antitumor Immunity Immunological Memory
BRIEF

published on 11/07/2024 at 15:05, 6 months 23 days ago

Xenetic Biosciences étend son partenariat avec Scripps pour renforcer son programme d'oncologie DNase

Traitement Du Cancer Collaboration En Recherche Oncologie DNase Thérapie Par Cellules CAR-T Développement Préclinique

Accesswire

Published on 05/30/2025 at 15:00, 23 minutes ago

Future Fuels and VRIFY Forge Partnership to Advance District-Scale Uranium Exploration in Nunavut's Hornby Basin
Published on 05/30/2025 at 15:00, 23 minutes ago

Nexalin and FatPipe Interviews to Air on the RedChip Small Stocks, Big Money(TM) Show on Bloomberg TV
Published on 05/30/2025 at 14:30, 53 minutes ago

Abasca Resources Files NI 43-101 Technical Report on its Loki Flake Graphite Deposit Confirming Initial Resource Estimate
Published on 05/30/2025 at 14:30, 53 minutes ago

Rio Grande Resources Announces Non-Brokered Private Placement
Published on 05/30/2025 at 14:21, 1 hour 2 minutes ago

First Quarter 2025 Financial Statements and MD&A

View all ACCESSWIRE

EQS Group

Published on 05/30/2025 at 15:05, 18 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Qualcomm Incorporated
Published on 05/30/2025 at 15:05, 18 minutes ago

Nebius participates in ClickHouse Series C; crystallizes value of asset to fund hypergrowth of core AI infrastructure business
Published on 05/30/2025 at 15:04, 19 minutes ago

Form 8.3 - The Vanguard Group, Inc.: American Axle & Manufacturing Holdings, Inc.
Published on 05/30/2025 at 15:04, 19 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Mural Oncology plc
Published on 05/30/2025 at 15:03, 20 minutes ago

Form 8.3 - The Vanguard Group, Inc.: Direct Line Insurance Group plc

Les Echos

Published on 05/28/2025 at 23:00, 1 day 16 hours ago

Standstill Commitments to hold shares of the company
Published on 05/28/2025 at 23:00, 1 day 16 hours ago

Engagements collectifs de conservation de titres de la société
Published on 05/28/2025 at 18:39, 1 day 20 hours ago

Descriptif du programme de rachat d'actions - Mai 2025
Published on 05/28/2025 at 18:39, 1 day 20 hours ago

Description of share-buyback program - May 2025
Published on 05/28/2025 at 18:34, 1 day 20 hours ago

AXA a placé 1 milliard d’euros d’Obligations Restricted Tier 1 et 1 milliard d’euros d’Obligations Tier 2

View all LES ECHOS COMFI WIRE